BC99 (10B CFU/day, 60 days) improves liver/kidney function & gut microbiota in alcohol drinkers, significantly lowering ALT/AST/BUN/Cr.

Improvement of Allergic Rhinitis in Adults by BC99 Improvement of Allergic Rhinitis in Children by BC99

BC99 Promotes Protein Digestion and Metabolism in Active Individuals

As of February 2026, more than 1,000 subjectsacross all age groups-including children, adults, andthe elderly-have been enrolled in clinical trialsinvolving BC99. Among the clinical interventionregimens, the maximum daily dosage administeredwas 48 billion CFU, with the longest interventionduration lasting up to 12 weeks.No serious adverse events (SAEs) associated withBC99 were reported in any dosage group or agesubgroup throughout the entire clinical trial period.

As of February 2026, more than 1,000 subjectsacross all age groups-including children, adults, andthe elderly-have been enrolled in clinical trialsinvolving BC99. Among the clinical interventionregimens, the maximum daily dosage administeredwas 48 billion CFU, with the longest interventionduration lasting up to 12 weeks.No serious adverse events (SAEs) associated withBC99 were reported in any dosage group or agesubgroup throughout the entire clinical trial period.

As of February 2026,approximately 14 animal studies have been conducted on BC99.Utilizing various animal models, these studies have provided in-depth insights into the effects and mechanisms of BC99 on intestinal microbiota,intestinal barrier function,intestinal metabolism,intestinal immunity, and intestinal motility.